Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up

Emilie van Lingen; M.E. Tushuizen; M.E.J. Steenhuis; T. van Deynen; J. Martens; D. Diaz-Infante Morales; A.E. van der Meulen-de Jong; I. Molendijk; S. van der Marel; P.W.J. Maljaars

doi:10.1007/s00384-021-04065-8

Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up

Emilie van Lingen^*, M.E. Tushuizen, M.E.J. Steenhuis, T. van Deynen, J. Martens, D. Diaz-Infante Morales, A.E. van der Meulen-de Jong, I. Molendijk, S. van der Marel, P.W.J. Maljaars

^*Corresponding author for this work

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

Abstract

PURPOSE: Liver steatosis is a frequently reported condition in patients with inflammatory bowel disease (IBD). Different factors, both metabolic and IBD-associated, are believed to contribute to the pathogenesis. The aim of our study was to calculate the prevalence of liver steatosis and fibrosis in IBD patients and to evaluate which factors influence changes in steatosis and fibrosis during follow-up.

METHODS: From June 2017 to February 2018, demographic and biochemical data was collected at baseline and after 6-12 months. Measured by transient elastography (FibroScan), liver steatosis was defined as Controlled Attenuation Parameter (CAP) ≥248 and fibrosis as liver stiffness value (Emed) ≥7.3 kPa. IBD disease activity was defined as C-reactive protein (CRP) ≥10 mg/l and/or fecal calprotectin (FCP) ≥150 μg/g. Univariate and multivariate regression analysis was performed; a p-value of ≤0.05 was considered significant.

RESULTS: Eighty-two out of 112 patients were seen for follow-up; 56% were male. The mean age was 43 ± 16.0 years, and mean BMI was 25.1 ± 4.7 kg/m2. The prevalence of liver steatosis was 40% and of fibrosis was 20%. At baseline, 26 patients (32%) had an active episode of IBD. Using a multivariate analysis, disease activity at baseline was associated with an increase in liver steatosis (B = 37, 95% CI 4.31-69.35, p = 0.027) and liver fibrosis (B = 1.2, 95% CI 0.27-2.14, p = 0.016) during follow-up.

CONCLUSIONS: This study confirms the relatively high prevalence of liver steatosis and fibrosis in IBD patients. We demonstrate that active IBD at baseline is associated with both an increase in liver steatosis and fibrosis during follow-up.

Original language	English
Pages (from-to)	349-356
Number of pages	8
Journal	International Journal of Colorectal Disease
Volume	37
Issue number	2
Early online date	17 Nov 2021
DOIs	https://doi.org/10.1007/s00384-021-04065-8
Publication status	Published - Feb 2022

Bibliographical note

Access to Document

10.1007/s00384-021-04065-8

Cite this

van Lingen, E., Tushuizen, M. E., Steenhuis, M. E. J., van Deynen, T., Martens, J., Morales, D. D.-I., van der Meulen-de Jong, A. E., Molendijk, I., van der Marel, S., & Maljaars, P. W. J. (2022). Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up. International Journal of Colorectal Disease, 37(2), 349-356. https://doi.org/10.1007/s00384-021-04065-8

@article{5860dc5836f94b7385d63ff2ed20ffd2,

title = "Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up",

abstract = "PURPOSE: Liver steatosis is a frequently reported condition in patients with inflammatory bowel disease (IBD). Different factors, both metabolic and IBD-associated, are believed to contribute to the pathogenesis. The aim of our study was to calculate the prevalence of liver steatosis and fibrosis in IBD patients and to evaluate which factors influence changes in steatosis and fibrosis during follow-up.METHODS: From June 2017 to February 2018, demographic and biochemical data was collected at baseline and after 6-12 months. Measured by transient elastography (FibroScan), liver steatosis was defined as Controlled Attenuation Parameter (CAP) ≥248 and fibrosis as liver stiffness value (Emed) ≥7.3 kPa. IBD disease activity was defined as C-reactive protein (CRP) ≥10 mg/l and/or fecal calprotectin (FCP) ≥150 μg/g. Univariate and multivariate regression analysis was performed; a p-value of ≤0.05 was considered significant.RESULTS: Eighty-two out of 112 patients were seen for follow-up; 56\% were male. The mean age was 43 ± 16.0 years, and mean BMI was 25.1 ± 4.7 kg/m2. The prevalence of liver steatosis was 40\% and of fibrosis was 20\%. At baseline, 26 patients (32\%) had an active episode of IBD. Using a multivariate analysis, disease activity at baseline was associated with an increase in liver steatosis (B = 37, 95\% CI 4.31-69.35, p = 0.027) and liver fibrosis (B = 1.2, 95\% CI 0.27-2.14, p = 0.016) during follow-up.CONCLUSIONS: This study confirms the relatively high prevalence of liver steatosis and fibrosis in IBD patients. We demonstrate that active IBD at baseline is associated with both an increase in liver steatosis and fibrosis during follow-up.",

author = "\{van Lingen\}, Emilie and M.E. Tushuizen and M.E.J. Steenhuis and \{van Deynen\}, T. and J. Martens and Morales, \{D. Diaz-Infante\} and \{van der Meulen-de Jong\}, A.E. and I. Molendijk and \{van der Marel\}, S. and P.W.J. Maljaars",

note = "{\textcopyright} 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2022",

month = feb,

doi = "10.1007/s00384-021-04065-8",

language = "English",

volume = "37",

pages = "349--356",

journal = "International Journal of Colorectal Disease",

issn = "0179-1958",

publisher = "Springer Nature",

number = "2",

}

van Lingen, E, Tushuizen, ME, Steenhuis, MEJ, van Deynen, T, Martens, J, Morales, DD-I, van der Meulen-de Jong, AE, Molendijk, I, van der Marel, S & Maljaars, PWJ 2022, 'Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up', International Journal of Colorectal Disease, vol. 37, no. 2, pp. 349-356. https://doi.org/10.1007/s00384-021-04065-8

Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up. / van Lingen, Emilie; Tushuizen, M.E.; Steenhuis, M.E.J. et al.
In: International Journal of Colorectal Disease, Vol. 37, No. 2, 02.2022, p. 349-356.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up

AU - van Lingen, Emilie

AU - Tushuizen, M.E.

AU - Steenhuis, M.E.J.

AU - van Deynen, T.

AU - Martens, J.

AU - Morales, D. Diaz-Infante

AU - van der Meulen-de Jong, A.E.

AU - Molendijk, I.

AU - van der Marel, S.

AU - Maljaars, P.W.J.

PY - 2022/2

Y1 - 2022/2

N2 - PURPOSE: Liver steatosis is a frequently reported condition in patients with inflammatory bowel disease (IBD). Different factors, both metabolic and IBD-associated, are believed to contribute to the pathogenesis. The aim of our study was to calculate the prevalence of liver steatosis and fibrosis in IBD patients and to evaluate which factors influence changes in steatosis and fibrosis during follow-up.METHODS: From June 2017 to February 2018, demographic and biochemical data was collected at baseline and after 6-12 months. Measured by transient elastography (FibroScan), liver steatosis was defined as Controlled Attenuation Parameter (CAP) ≥248 and fibrosis as liver stiffness value (Emed) ≥7.3 kPa. IBD disease activity was defined as C-reactive protein (CRP) ≥10 mg/l and/or fecal calprotectin (FCP) ≥150 μg/g. Univariate and multivariate regression analysis was performed; a p-value of ≤0.05 was considered significant.RESULTS: Eighty-two out of 112 patients were seen for follow-up; 56% were male. The mean age was 43 ± 16.0 years, and mean BMI was 25.1 ± 4.7 kg/m2. The prevalence of liver steatosis was 40% and of fibrosis was 20%. At baseline, 26 patients (32%) had an active episode of IBD. Using a multivariate analysis, disease activity at baseline was associated with an increase in liver steatosis (B = 37, 95% CI 4.31-69.35, p = 0.027) and liver fibrosis (B = 1.2, 95% CI 0.27-2.14, p = 0.016) during follow-up.CONCLUSIONS: This study confirms the relatively high prevalence of liver steatosis and fibrosis in IBD patients. We demonstrate that active IBD at baseline is associated with both an increase in liver steatosis and fibrosis during follow-up.

AB - PURPOSE: Liver steatosis is a frequently reported condition in patients with inflammatory bowel disease (IBD). Different factors, both metabolic and IBD-associated, are believed to contribute to the pathogenesis. The aim of our study was to calculate the prevalence of liver steatosis and fibrosis in IBD patients and to evaluate which factors influence changes in steatosis and fibrosis during follow-up.METHODS: From June 2017 to February 2018, demographic and biochemical data was collected at baseline and after 6-12 months. Measured by transient elastography (FibroScan), liver steatosis was defined as Controlled Attenuation Parameter (CAP) ≥248 and fibrosis as liver stiffness value (Emed) ≥7.3 kPa. IBD disease activity was defined as C-reactive protein (CRP) ≥10 mg/l and/or fecal calprotectin (FCP) ≥150 μg/g. Univariate and multivariate regression analysis was performed; a p-value of ≤0.05 was considered significant.RESULTS: Eighty-two out of 112 patients were seen for follow-up; 56% were male. The mean age was 43 ± 16.0 years, and mean BMI was 25.1 ± 4.7 kg/m2. The prevalence of liver steatosis was 40% and of fibrosis was 20%. At baseline, 26 patients (32%) had an active episode of IBD. Using a multivariate analysis, disease activity at baseline was associated with an increase in liver steatosis (B = 37, 95% CI 4.31-69.35, p = 0.027) and liver fibrosis (B = 1.2, 95% CI 0.27-2.14, p = 0.016) during follow-up.CONCLUSIONS: This study confirms the relatively high prevalence of liver steatosis and fibrosis in IBD patients. We demonstrate that active IBD at baseline is associated with both an increase in liver steatosis and fibrosis during follow-up.

UR - https://www.scopus.com/pages/publications/85119170871

U2 - 10.1007/s00384-021-04065-8

DO - 10.1007/s00384-021-04065-8

M3 - Article

C2 - 34791524

SN - 0179-1958

VL - 37

SP - 349

EP - 356

JO - International Journal of Colorectal Disease

JF - International Journal of Colorectal Disease

IS - 2

ER -

Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this